Aclaris Therapeutics, Inc. (ACRS): Capital Expenditures
$111.0K
Year ended 2025-12-31
$118.0K
Trailing 12 months to 2026-06-30
-43.2%
3-year compound annual growth
-24.5%
5-year compound annual growth
-14.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $111.0K | -8.3% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $121.0K | -90.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.31M | +116.4% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $605.0K | +96.4% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $308.0K | -32.0% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $453.0K | -71.9% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $1.61M | +19.0% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $1.36M | +9.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $1.24M | +432.3% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $232.0K | -54.2% | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $507.0K | +21.6% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $417.0K | n/a | 2017-03-15, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $719.0K | +96.4% |
Compare ACRS, BOLT, ADAG, XENE side by side · Screen every company in Pharmaceutical Preparations ↗